CA2391499A1 - Compositions and methods for treatment of allergic disorders - Google Patents
Compositions and methods for treatment of allergic disorders Download PDFInfo
- Publication number
- CA2391499A1 CA2391499A1 CA002391499A CA2391499A CA2391499A1 CA 2391499 A1 CA2391499 A1 CA 2391499A1 CA 002391499 A CA002391499 A CA 002391499A CA 2391499 A CA2391499 A CA 2391499A CA 2391499 A1 CA2391499 A1 CA 2391499A1
- Authority
- CA
- Canada
- Prior art keywords
- bacteria
- probiotic bacteria
- administration
- administered
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 208000010668 atopic eczema Diseases 0.000 title claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- 230000000172 allergic effect Effects 0.000 title description 3
- 241000894006 Bacteria Species 0.000 claims abstract description 99
- 239000006041 probiotic Substances 0.000 claims abstract description 64
- 230000000529 probiotic effect Effects 0.000 claims abstract description 64
- 235000018291 probiotics Nutrition 0.000 claims abstract description 64
- 208000026935 allergic disease Diseases 0.000 claims abstract description 25
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 10
- 230000007815 allergy Effects 0.000 claims abstract description 10
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 239000013566 allergen Substances 0.000 claims description 43
- 230000001580 bacterial effect Effects 0.000 claims description 31
- 241000894007 species Species 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
- 206010016946 Food allergy Diseases 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 230000036783 anaphylactic response Effects 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 231100000740 envenomation Toxicity 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000001932 seasonal effect Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 description 25
- 229940092253 ovalbumin Drugs 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 230000004044 response Effects 0.000 description 20
- 230000001629 suppression Effects 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 206010051841 Exposure to allergen Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ4158A AUPQ415899A0 (en) | 1999-11-19 | 1999-11-19 | Compositions for and methods of treatment of allergic diseases |
| AUPQ4158 | 1999-11-19 | ||
| PCT/AU2000/001414 WO2001037865A1 (en) | 1999-11-19 | 2000-11-20 | Compositions and methods for treatment of allergic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2391499A1 true CA2391499A1 (en) | 2001-05-31 |
Family
ID=3818302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002391499A Abandoned CA2391499A1 (en) | 1999-11-19 | 2000-11-20 | Compositions and methods for treatment of allergic disorders |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1229930A4 (de) |
| JP (1) | JP2003514869A (de) |
| KR (1) | KR20020084066A (de) |
| CN (1) | CN1391480A (de) |
| AU (1) | AUPQ415899A0 (de) |
| BR (1) | BR0015698A (de) |
| CA (1) | CA2391499A1 (de) |
| HK (1) | HK1049115A1 (de) |
| WO (1) | WO2001037865A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9427012B2 (en) | 2010-08-10 | 2016-08-30 | R.P. Scherer Technologies, Llc | Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| JP4212838B2 (ja) | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
| AU2004233658B2 (en) * | 2003-03-13 | 2009-10-29 | Kirin Holdings Kabushiki Kaisha | Antiallergic composition |
| JP4712289B2 (ja) * | 2003-08-26 | 2011-06-29 | 株式会社エイ・エル・エイ | 免疫促進用組成物 |
| JP4591810B2 (ja) * | 2003-09-19 | 2010-12-01 | 日之出産業株式会社 | 花粉症アレルギー性鼻炎抑制用点鼻組成物 |
| AU2004298384A1 (en) * | 2003-12-17 | 2005-06-30 | N.V. Nutricia | Lactic acid producing bacteria and lung function |
| US7955834B2 (en) | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
| TWI356680B (en) * | 2007-01-05 | 2012-01-21 | Promd Biotech Co Ltd | Anti-allergy lactic acid bacteria |
| CN102657260B (zh) * | 2007-06-21 | 2013-08-21 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
| CN101328468B (zh) * | 2007-06-21 | 2012-05-23 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
| EP2065048A1 (de) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung |
| PT2244734T (pt) | 2008-02-01 | 2016-08-05 | Murdoch Childrens Res Inst | Método para induzir tolerância a um alérgeno |
| KR101311989B1 (ko) * | 2010-11-17 | 2013-09-26 | 주식회사한국야쿠르트 | 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품 |
| EP3738599B1 (de) * | 2018-01-12 | 2023-12-27 | GI Innovation, Inc. | Zusammensetzung mit probiotika und polypeptid mit bindungsaffinität für ige und verwendung davon |
| CN111296842B (zh) * | 2020-02-14 | 2021-01-05 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
| CN112375722B (zh) * | 2021-01-18 | 2021-04-13 | 山东中科嘉亿生物工程有限公司 | 一种改善过敏的干酪乳杆菌lc-12及其产品、应用 |
| WO2024081219A1 (en) | 2022-10-14 | 2024-04-18 | Csp Technologies, Inc. | Container and method for storing and stabilizing moisture sensitive products |
| CN117085046A (zh) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | 嗜酸乳杆菌ls001后生元及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5946488B2 (ja) | 1978-08-07 | 1984-11-13 | 極東脂肪酸株式会社 | アレルギ−反応抑制剤 |
| JPS5946491B2 (ja) | 1979-03-14 | 1984-11-13 | 極東脂肪酸株式会社 | 喘息治療剤 |
| JPH07265064A (ja) | 1993-11-23 | 1995-10-17 | Taketoshi Yamada | 腸内細菌叢改善組成物 |
| JPH092959A (ja) | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | ＩｇＥ抗体産生抑制剤および抗アレルギー剤 |
| EP0904784A1 (de) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotisches Ernährungspräparat |
| JPH11199495A (ja) * | 1998-01-10 | 1999-07-27 | Nichinichi Seiyaku Kk | 腸溶性カプセルを用いた抗アレルギー剤 |
| IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| JP4074006B2 (ja) * | 1998-06-24 | 2008-04-09 | アサマ化成株式会社 | ＩｇＥ抗体産生抑制物質の製造方法並びにそれを用いた食品 |
-
1999
- 1999-11-19 AU AUPQ4158A patent/AUPQ415899A0/en not_active Abandoned
-
2000
- 2000-11-20 WO PCT/AU2000/001414 patent/WO2001037865A1/en active Search and Examination
- 2000-11-20 JP JP2001539479A patent/JP2003514869A/ja not_active Withdrawn
- 2000-11-20 BR BR0015698-1A patent/BR0015698A/pt not_active IP Right Cessation
- 2000-11-20 EP EP00975685A patent/EP1229930A4/de not_active Withdrawn
- 2000-11-20 CN CN00815855A patent/CN1391480A/zh active Pending
- 2000-11-20 KR KR1020027006409A patent/KR20020084066A/ko not_active Application Discontinuation
- 2000-11-20 CA CA002391499A patent/CA2391499A1/en not_active Abandoned
-
2003
- 2003-02-11 HK HK03100999.8A patent/HK1049115A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9427012B2 (en) | 2010-08-10 | 2016-08-30 | R.P. Scherer Technologies, Llc | Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1049115A1 (zh) | 2003-05-02 |
| KR20020084066A (ko) | 2002-11-04 |
| BR0015698A (pt) | 2002-07-23 |
| WO2001037865A1 (en) | 2001-05-31 |
| EP1229930A1 (de) | 2002-08-14 |
| EP1229930A4 (de) | 2004-09-22 |
| CN1391480A (zh) | 2003-01-15 |
| JP2003514869A (ja) | 2003-04-22 |
| AUPQ415899A0 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2391499A1 (en) | Compositions and methods for treatment of allergic disorders | |
| Blumchen et al. | Oral peanut immunotherapy in children with peanut anaphylaxis | |
| Jirillo et al. | Anti-inflammatory and anti-allergic properties of donkey’s and goat’s milk | |
| US10071157B2 (en) | Method of inducing tolerance to an allergen | |
| Velez et al. | Probiotic fermented milk consumption modulates the allergic process induced by ovoalbumin in mice | |
| JP2004512307A (ja) | 心血管障害の診断および治療のための組成物および方法 | |
| Huber et al. | Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89 | |
| Shamsuzzaman et al. | Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses | |
| AU782689B2 (en) | Compositions and methods for treatment of allergic disorders | |
| RU2602771C2 (ru) | Вакцина мбтк против астмы | |
| AP1044A (en) | Mycobacterium vaccae for down-regulation of the TH2 activity of the immune system. | |
| Christensen et al. | Low-dose oral tolerance due to antigen in the diet suppresses differentially the cholera toxin-adjuvantized IgE, IgA and IgG response | |
| Frøkiær | Probiotics and the Immune System | |
| Wallace et al. | Protection against non‐typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: Role of specific antibody and phagocytes | |
| WO2021162563A1 (en) | Lipopolysaccharides for treating food allergies | |
| KR101275227B1 (ko) | 중증근무력증 예방, 개선 또는 치료용 조성물 | |
| Chudzik-Kozłowska et al. | BALB/C mice as a model for immunogenicity testing of food proteins on the example of egg ovalbumin | |
| McClemens | The effect of Lactobacillus reuteri on host immune and cell alterations during an enteric parasitic infection | |
| Viljanen | Effects of probiotic bacteria on symptoms and on immunologic responses in infants with atopic dermatitis | |
| MXPA99005553A (en) | Mycobacterium vaccae | |
| Crittenden et al. | The MAM Study: a clinical study of milk allergy mechanisms in adults | |
| Mustonen | The role of inflammation and its environmental triggers in allergic diseases | |
| Zhu | Impact of gram-negative bacteria on the allergic immune response in a mouse model of allergen-induced eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |